BREYANZI is a prescription medicine used to treat large B cell lymphoma, a type of non-Hodgkin lymphoma, when:
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Karla was part of the Breyanzi clinical trial, and the FDA approved Breyanzi for use after a patient’s first treatment in June 2022.
When Breyanzi was given to me as an option, I was unsure. And now that I've done it, I know I did the right thing for me. I'm the living, breathing proof of it. It worked for me.
—Karla